Viscosupplementation Market Share, Size, Trends, Industry Analysis Report, By Product (Three Injection, Five Injection, Single Injection); By End-Use; By Region; Segment Forecast, 2024 - 2032
- Published Date:Jan-2024
- Pages: 119
- Format: PDF
- Report ID: PM1015
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
The global Viscosupplementation Market is projected to witness robust growth. It was valued at USD 5.27 billion in 2023 and is projected to grow to USD 12.94 Billion By 2032, exhibiting a CAGR of 10.6% over the forecast period, 2024 – 2032
Viscosupplementation is a minimally invasive medical procedure involving direct injection of a gel-like fluid, consisting of exogenous hyaluronic acid (HA) derivatives, into the knee joints. This fluid acts as a lubricant, facilitating smooth bone movement, reducing inflammation, and serving as a shock absorber for joint loads. By decreasing friction during movements, enhancing synovial fluid cushioning, alleviating severe pain, and improving joint range of motion, viscosupplementation offers comprehensive benefits. Additionally, it restores the rheological properties of synovial fluids, providing mechanical, analgesic, anti-inflammatory, and chondroprotective effects. Consequently, viscosupplementation finds extensive application in treating osteoarthritis of the knee, hip, and hand, currently available in intermediate, low, and high molecular weights.
To Understand More About this Research: Request a Free Sample Report
Furthermore, the market is poised for growth driven by increasing demand for non-surgical osteoarthritis solutions, the prevalence of lifestyle-related conditions, and advancements in therapies utilizing hyaluronic acid. The proven clinical effectiveness of available viscosupplements positions them as the most efficient treatment for knee osteoarthritis, contributing to market expansion. Moreover, the rising geriatric population, with nearly half (49.6%) of individuals aged 65 or older diagnosed with arthritis, according to CDC data, further fuels market growth. Viscosupplementation is highly sought after among the elderly, offering relief from joint pain, improved mobility, and a non-surgical alternative for osteoarthritis management, ultimately enhancing the quality of life for older individuals.
The increasing preference for single-injection therapy for osteoarthritis is expected to drive market growth in the forecast period. Other notable contributors to osteoarthritis and osteoporosis in the growing population include the adoption of smoking, a sedentary lifestyle, and lifestyle changes. Knee osteoarthritis is a common ailment among older people.
The rising incidence of hypertension, cardiovascular diseases, obesity, depression, renal failure, and gastrointestinal bleeding is anticipated to elevate the demand for viscosupplement treatment, thereby boosting the market over the evaluation period.
Industry Dynamics
Growth Drivers
- The rising prevalence of knee osteoarthritis.
Knee osteoarthritis is a prevalent condition among the elderly, and the increasing instances of hypertension, depression, obesity, renal failure, cardiovascular diseases, and gastrointestinal bleeding are anticipated to drive the demand for viscosupplement therapy, thereby boosting the market's Compound Annual Growth Rate (CAGR) during the assessment period. Furthermore, key players in the market are directing their efforts toward developing cross-linked hyaluronic acid for immediate pain relief. This ongoing advancement presents a significant opportunity for enhancement.
France features a robust reimbursement policy for viscosupplements, with 12 out of the 13 products designed for knee osteoarthritis treatment qualifying for reimbursement of up to 65% through social security. Consequently, the anticipated impact of beneficial reimbursement policies targeted at the senior population is expected to propel the growth of viscosupplementation market revenue.
Report Segmentation
The market is primarily segmented based on product, end-use, and region.
|
By Product |
By End-Use |
By Region |
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Product Analysis
- The Three Injection segment held the largest revenue share in 2022
The preferred method for treating osteoarthritis is the three-injection procedure, widely chosen by medical practitioners due to its effectiveness. This approach is often favored to mitigate the need for total knee replacement surgery in osteoarthritis cases. The market share is influenced by the availability of various three-injection segments. Moreover, numerous clinical trials have been approved, demonstrating positive results for three-injection procedures in the treatment of osteoarthritis.
This, coupled with investments in research and development and the increasing demand to address the ailment, is expected to propel market growth during the forecast period. The single-injection segment is anticipated to experience the highest growth rate over this period. Despite being relatively new in the market, these injections exhibit promising growth due to their shorter regimen, reduced hospital visits, and fewer adverse effects and associated pain. An example of a single-injection viscosupplement is Gel-One by Zimmer Biomet, the first low-volume formula of its kind, designed for patients unresponsive to other conservative treatments.
By End-Use Analysis
- The Orthopedic Clinics/ASCs segment accounted for the highest market share during the forecast period
Owing to the increased demand for outpatient surgeries, orthopedic clinics specialize in the care of the musculoskeletal system, addressing both surgical and nonsurgical issues related to the spine, joints, ligaments, bones, muscles, and nerves. The growing prevalence of osteoarthritis among older people is a significant factor anticipated to boost the growth of this segment.
The segment is expected to experience rapid growth, particularly in Ambulatory Surgical Centers (ASCs), which can efficiently conduct same-day surgeries for procedures like ACL surgery, hip, knee, and shoulder replacements, among others. These surgeries are relatively uncomplicated and often require minimal hospitalization. Additionally, ASCs enable orthopedic clinics to accommodate a higher volume of patients daily. However, hospitals are projected to maintain growth in the coming years, driven by advancements in medical technology and the emergence of multispecialty hospitals. According to the Global RA Network, the global arthritis prevalence exceeded 350 million people in 2021, and this number is continually increasing, primarily due to the aging demographic. Consequently, the expansion of both clinics and hospitals
Regional Insights
- Asia Pacific dominated the largest market in 2022
The growth of the market in this region is significantly fueled by the presence of a vulnerable geriatric population prone to osteoarthritis. Additionally, various initiatives aimed at fortifying the market contribute to its expansion. For instance, in April 2022, the agreement between Juniper Biologics and Kolon Life pertains to the advancement and marketing of TissueGene-C low dose, an experimental treatment for knee osteoarthritis.
Administered through a single intra-articular injection, it eliminates the need for surgery. In accordance with the agreement, Juniper is tasked with the development and promotion of the gene therapy to medical professionals and hospitals in the Asia Pacific region.
Europe is anticipated to have the highest growth rate in the forecast period, it is propelled by factors like the increasing geriatric population and augmented investments from market players. Annually, osteoporosis affects more than 2.5 million women in both the UK and France.
Key Market Players & Competitive Insights
The market is characterized by intense competition, with established players relying on advanced technology, high-quality products, and a strong brand image to drive revenue growth. These companies employ various strategies such as research and development, mergers and acquisitions, and technological innovations to expand their product portfolios and maintain a competitive edge in the market.
Some of the major players operating in the global market include:
- Anika Therapeutics, Inc.
- DePuy Synthes
- F.Hoffmann-La Roche Ltd.
- Ferring Pharmaceuticals B.V.
- Fidia Farmaceutici S.p.A
- LG Life Sciences Ltd.
- Lifecore Biomedical
- Sanofi
- Seikagaku Corp.
- Smith & Nephew PLC
- Zimmer Biomet
Recent Developments
- In November 2022, Anika Therapeutics, Inc., a prominent joint preservation company, has effectively met the primary endpoint in the Phase III Study for Cingal. This medication is formulated to offer prolonged pain relief for individuals dealing with knee osteoarthritis (OA). The company is focused on securing FDA clearance for Cingal and its introduction to the United States. Successful trials of this nature empower companies to enhance their research and development endeavors, providing them with a competitive edge in the market.
- In April 2022, Juniper Biologics and Kolon Life Sciences have entered into a licensing arrangement to develop and commercialize TissueGene-C low dose (TG-C LD), an investigational therapy tailored for non-surgical treatment through a single intra-articular injection, specifically addressing knee osteoarthritis. As per the terms of the licensing agreement, Juniper will lead the efforts in developing and promoting this gene therapy, with a focus on medical professionals and hospitals in the Asia-Pacific, Middle East, and Africa regions.
- In march 2021, Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation introduced JOYCLU 30mg intra-articular injection, a therapeutic agent aimed at enhancing joint function. Seikagaku obtained the manufacturing and marketing approval for this product in Japan.
Viscosupplementation Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 5.79 billion |
|
Revenue forecast in 2032 |
USD 12.94 billion |
|
CAGR |
10.6% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments Covered |
By Product, By End-Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
Seeking a more personalized report that meets your specific business needs? At Polaris Market Research, we’ll customize the research report for you. Our custom research will comprehensively cover business data and information you need to make strategic decisions and stay ahead of the curve.
FAQ's
key companies in Viscosupplementation Market are Anika Therapeutics, Inc., DePuy Synthes, F.Hoffmann-La Roche Ltd., Ferring Pharmaceuticals B.V
The global Viscosupplementation market is expected to grow at a CAGR of 10.5% during the forecast period.
The viscosupplementation market report covering key segments are product, end-use, and region.
key driving factors in Viscosupplementation Market are the rising prevalence of knee osteoarthritis
The global viscosupplementation market size is expected to reach USD 12.94 billion by 2032
© 2024 Polaris Market Research and Consulting. All rights reserved
